Skip to main content

Table 1 (abstract O23). Proportion of responders who maintained optimal control of disease activity* at the end of epoch 4, following treatment with canakinumab (Week 112 analysis)

From: Proceedings of the 25th European Paediatric Rheumatology Congress (PReS 2018)

Cohort

150 mg q8w

n (%)

150 mg q4w

n (%)

300 mg q8w

n (%)

300 mg q4w

n (%)

crFMF (N=57)

23 (40.4)

20 (35.1)

5 (8.8)

9 (15.8)

TRAPS (N=50)

25 (50.0)

5 (10.0)

9 (18.0)

11 (22.0)

HIDS/MKD (N=64)

14 (21.9)

7 (10.9)

11 (17.2)

32 (50.0)

  1. *Optimal control of disease activity was defined as median of no or 1 flare, and no uptitration